Bonnie Anderson is the President and Chief Executive Officer of Veracyte, a molecular diagnostics company that is pioneering the field of molecular cytology. Her career spans nearly 30 years in regulated diagnostics and life science markets. Ms. Anderson cofounded Veracyte in 2008, took the company public in 2013 and has spearheaded Veracyte's commercialization successes to date. These include the introduction of its first product - the Afirma® Thyroid FNA Analysis - which is becoming a new standard of care in thyroid cancer diagnosis by helping patients with thyroid nodules avoid unnecessary surgery and by reducing healthcare costs. In April 2015, Veracyte entered the pulmonology market with the launch of its second product - the PerceptaTM Bronchial Genomic Classifier - to help reduce unnecessary invasive procedures in lung cancer diagnosis.
Prior to Veracyte, Ms. Anderson provided strategic consulting services to venture capital firms and early-stage businesses following 18 years in leadership positions at Beckman Coulter. She graduated from Indiana University of Pennsylvania with a Bachelor's of Science degree in Medical Technology and in 2012 was honored with a "Distinguished Alumni" award. In 2015, Fast Company magazine named Ms. Anderson to its "100 Most Creative People in Business" list. She was named one of the "Most Influential Women in Bay Area Business" (2013) and one of the "Bay Area's Most Admired CEOs" (2014) by the San Francisco Business Times, and has also received the Silicon Valley Business Journal's "Women of Influence" award (2013).